7UL7 image
Entry Detail
PDB ID:
7UL7
EMDB ID:
Title:
Lineage I (Pinneo) Lassa virus glycoprotein bound to 18.5C-M30 Fab
Biological Source:
PDB Version:
Deposition Date:
2022-04-04
Release Date:
2022-06-15
Method Details:
Experimental Method:
Resolution:
3.59 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Glycoprotein G1
Mutations:Residues 255-258 mutated from RRLL to RRRR
Chain IDs:A (auth: C), D (auth: A), G (auth: B)
Chain Length:206
Number of Molecules:3
Biological Source:Lassa mammarenavirus
Polymer Type:polypeptide(L)
Description:18.5C-M30 Fab Light Chain
Chain IDs:B (auth: D), E (auth: L), H (auth: F)
Chain Length:237
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:18.5C-M30 Fab Heavy Chain
Chain IDs:C (auth: E), F (auth: H), I (auth: G)
Chain Length:249
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Glycoprotein G2
Chain IDs:J (auth: c), K (auth: b), L (auth: a)
Chain Length:206
Number of Molecules:3
Biological Source:Lassa mammarenavirus
Ligand Molecules
Primary Citation
Neutralizing Antibodies against Lassa Virus Lineage I.
Mbio 13 e0127822 e0127822 (2022)
PMID: 35730904 DOI: 10.1128/mbio.01278-22

Abstact

Lassa virus (LASV) is the causative agent of the deadly Lassa fever (LF). Seven distinct LASV lineages circulate through western Africa, among which lineage I (LI), the first to be identified, is particularly resistant to antibody neutralization. Lineage I LASV evades neutralization by half of known antibodies in the GPC-A antibody competition group and all but one of the antibodies in the GPC-B competition group. Here, we solve two cryo-electron microscopy (cryo-EM) structures of LI GP in complex with a GPC-A and a GPC-B antibody. We used complementary structural and biochemical techniques to identify single-amino-acid substitutions in LI that are responsible for immune evasion by each antibody group. Further, we show that LI infection is more dependent on the endosomal receptor lysosome-associated membrane protein 1 (LAMP1) for viral entry relative to LIV. In the absence of LAMP1, LI requires a more acidic fusion pH to initiate membrane fusion with the host cell relative to LIV. IMPORTANCE No vaccine or therapeutics are approved to prevent LASV infection or treat LF. All vaccine platforms currently under development present only the LIV GP sequence. However, our data suggest that the high genetic diversity of LASV may be problematic for designing both a broadly reactive immunogen and therapeutic. Here, we examine antibodies that are highly potent against LIV yet are ineffective against LI. By pinpointing LI mutations responsible for this decrease in antibody efficacy, we suggest that future vaccine platforms may need to incorporate specific LI-like mutations in order to generate a broadly neutralizing antibody response against all LASV lineages.

Legend

Protein

Chemical

Disease

Primary Citation of related structures